PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
Open Access
- 22 January 2008
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 105 (3), 985-990
- https://doi.org/10.1073/pnas.0711281105
Abstract
Angiogenesis and inflammation are central processes through which the tumor microenvironment influences tumor growth. We have demonstrated recently that peroxisome proliferator-activated receptor (PPAR)α deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of thrombospondin (TSP)-1 and prevents tumor growth. Hence, we speculated that pharmacologic activation of PPARα would promote tumor growth. Surprisingly, the PPARα agonist fenofibrate potently suppressed primary tumor growth in mice. This effect was not mediated by cancer-cell-autonomous antiproliferative mechanisms but by the inhibition of angiogenesis and inflammation in the host tissue. Although PPARα-deficient tumors were still susceptible to fenofibrate, absence of PPARα in the host animal abrogated the potent antitumor effect of fenofibrate. In addition, fenofibrate suppressed endothelial cell proliferation and VEGF production, increased TSP-1 and endostatin, and inhibited corneal neovascularization. Thus, both genetic abrogation of PPARα as well as its activation by ligands cause tumor suppression via overlapping antiangiogenic pathways. These findings reveal the potential utility of the well tolerated PPARα agonists beyond their use as lipid-lowering drugs in anticancer therapy. Our results provide a mechanistic rationale for evaluating the clinical benefits of PPARα agonists in cancer treatment, alone and in combination with other therapies.Keywords
This publication has 42 references indexed in Scilit:
- Clofibric acid, a peroxisome proliferator–activated receptor α ligand, inhibits growth of human ovarian cancerMolecular Cancer Therapeutics, 2007
- PPARα Deficiency in Inflammatory Cells Suppresses Tumor GrowthPLOS ONE, 2007
- Efficacy of peroxisome proliferative activated receptor (PPAR)-α ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine modelsAtherosclerosis, 2006
- Peroxisome-proliferator-activated receptor α agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1Biochemical Journal, 2006
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Melanoma Chemoprevention: A Role for Statins or Fibrates?Clinical Journal of Sport Medicine, 2003
- Inflammation and cancerNature, 2002
- Peroxisome proliferator–activated receptor α in the human breast cancer cell lines MCF‐7 and MDA‐MB‐231Molecular Carcinogenesis, 2002
- PPAR activators inhibit endothelial cell migration by targeting AktBiochemical and Biophysical Research Communications, 2002
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971